Raul R. Rodriguez - Jan 26, 2023 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
CEO, President, Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Jan 26, 2023
Transactions value $
-$35,595
Form type
4
Date filed
2/7/2023, 03:30 PM
Previous filing
Dec 30, 2022
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +300K +21.41% $0.00 1.7M Jan 26, 2023 Direct F1, F2
transaction RIGL Common Stock Sale -$35.6K -20.3K -1.2% $1.75 1.68M Feb 6, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +600K $0.00 600K Jan 26, 2023 Common Stock 600K $1.87 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024.
F2 Includes 9,277 shares acquired under the Issuer's stock purchase plan.
F3 These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.
F4 The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period.